Tradestie Institutional Equity Comparison Engine

IMCR vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IMCR Overall Edge

IMCR Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immunocore Holdings plc American Depositary Shares (IMCR) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, IMCR trades at 22.6x Forward P/E with -2.2% operating margin (-1.4% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, IMCR sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IMCR
IMCR 22.6x vs ZBIO N/M Fwd P/E
Growth & Margin Winner IMCR
Op Margin -2.2% vs -2747.5% ยท YoY -1.4% vs -100.0%
Momentum & Technical Winner IMCR
1Y -18.4% vs -21.7% ยท 52W Pos 10% vs 46%
Options & Structure Winner ZBIO
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (13th %ile IV)
IMCR NASDAQ
Immunocore Holdings plc American Depositary Shares
Biological Products, (No Disgnostic Substances)
$28.88
-3.54% 1D
Market Cap $1.5B
1M Return -1.77%
1Y Return -18.35%
Forward P/E 22.6x
Unified AI Score
46.3 / 100 HOLD
Tech 46.0 Fund 50.0 Flow 50.0 Mom 54.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IMCR -18.35% ZBIO -21.68% Spread: +3.33 pp (IMCR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IMCR TTM Op. Margin: -2.2% ZBIO TTM Op. Margin: -2747.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMCR vs ZBIO. Trailing 12-month operating profitability (IMCR -2.2% vs ZBIO -2747.5%) and valuation multiples (IMCR 22.6x vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IMCR (5) vs ZBIO (4)
Institutional Metric IMCR ZBIO Criterion Row Winner
Market Capitalization Scale $1.5B $1.9B Larger Scale ZBIO
Trailing P/E Ratio Valuation 23.8x N/M Lower Multiple IMCR
Forward P/E Ratio Valuation 22.6x N/M Lower Multiple IMCR
Revenue Growth (YoY) Growth -1.4% -100.0% Higher Growth IMCR
Operating Margin (TTM) Profitability -2.2% -2747.5% Higher Margin IMCR
Net Profit Margin Profitability -7.5% 0.0% Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency -7.9% -265.1% Higher ROE IMCR
52-Week Range Position Momentum 10% ($28โ€“$41) 46% ($14โ€“$45) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 0.63ฮฒ ยท 59% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IMCR vs ZBIO Buy Guide
IMCR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live IMCR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IMCR nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.